RVVTF — Revive Therapeutics: The peptide lesson Big Pharma is about to learn the hard way.
Eli Lilly just sued six companies for selling unapproved retatrutide. The drug hasn’t even finished Phase 3 yet, and the black-market peptide trade is already worth billions. That’s the tell. The multi-trillion-dollar peptide era is here, and the giants are scrambling because they lost control of the patents.
Peacetime bucillamine rights are a $5M option. A live chemical-threat scare in the Middle East is the one thing that turns it into a 90-day exclusivity check plus government-funded Animal Rule work. The science does not get better overnight. The buyer’s fear of being late does.
Not financial advice. Scenario, not news.
IMO: Bucillamine is the next one they should be eyeing and buying cheap right now.
Revive holds the rights. Granted Canadian Patent 3,172,170 covers bucillamine for infectious diseases — influenza, COVID-19 — expiring 2041. Fresh U.S. and Canadian filings under application 19/518,001 target nerve-agent exposure. There’s also a granted U.S. patent for gout and additional filings for stroke, brain injury, and migraines.
This isn’t theoretical. Bucillamine has over thirty years of clinical use in Japan and South Korea for rheumatoid arthritis. It’s a stronger antioxidant than NAC. And the latest animal data from Defence Research and Development Canada shows it preserved key brain receptors in nerve-agent models while avoiding the pulmonary hemorrhage seen with NAC.
That’s exactly the profile governments stockpile for. Canada and the U.S. already run biodefense programs. Middle East allies facing ongoing conflict need the same countermeasures. Revive is positioned for those contracts.
Market cap sits around nine million dollars. The asset is real, the IP is expanding, and the window for Big Pharma to lock in exclusive rights is closing fast — just like it did with the peptides.
The largest cartel in the world lost the ability to patent 100s of peptides. Small Compounding Pharmacies beat them to the punch.
Any smart, BIG Pharma market analysis, executives would be foolish not to believe "animal" data for efficiency based on bucillamine existing safety profile. Big Pharma owes this shareholders and remember the history lesson. War always brings profit for the right ones prepared and controlling it.